Rafael Tamayo-Rios
Granada, AN, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
The Current Role of Physiotherapy in Systemic Light-Chain (AL) Amyloidosis and Multiple Myeloma.
Journal: Life (Basel, Switzerland)
Published: May 21, 2026
The Evolving Landscape of Anti-Clonal Therapy in Newly Diagnosed Systemic Light-Chain (AL) Amyloidosis: Evidence- and Time-Based Comparison with Multiple Myeloma.
Journal: Life (Basel, Switzerland)
Published: January 21, 2026
Immune biomarkers of increased infection risk in multiple myeloma.
Journal: Blood
Published: September 22, 2025
Immune biomarkers of increased infection risk in multiple myeloma.
Journal: Blood
Published: September 22, 2025
Incidence and predictors of sudden death in patients with cardiac amyloidosis.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: October 25, 2024
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.
Journal: Clinical lymphoma, myeloma & leukemia
Published: October 22, 2024
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma.
Journal: Blood cancer discovery
Published: October 01, 2024
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 22, 2024
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.
Journal: Haematologica
Published: April 23, 2024
Last Updated: 09/26/2026